PTHLH and postmenopausal osteoporosis: Abaloparatide (Figure 2) is a novel synthetic 34-amino acid peptide analog of parathyroid hormone-related protein (PTHrP) that was approved in 2017 for postmenopausal osteoporosis as a physiological regulator of bone formation.